title: Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial.
authors.forename: J A
authors.initials: JA
authors.lastname: Norman
authors.forename: S
authors.initials: S
authors.lastname: Parker
authors.forename: D
authors.initials: D
authors.lastname: Lew
authors.forename: M
authors.initials: M
authors.lastname: Manthorpe
authors.forename: M
authors.initials: M
authors.lastname: Marquet
mesh_terms: D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004247:DNA; D004274:DNA, Recombinant; D015316:Genetic Therapy / Q000009:adverse effects; D015793:HLA-B7 Antigen / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D008055:Lipids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000628:therapy*; D010957:Plasmids / Q000009:adverse effects / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001613:beta 2-Microglobulin / Q000096:biosynthesis / Q000235:genetics
chemical_list: C096492:Allovectin-7; D004274:DNA, Recombinant; D015793:HLA-B7 Antigen; D008055:Lipids; D001613:beta 2-Microglobulin; D004247:DNA